FDA warning letter to Boothwyn Pharmacy cites insanitary conditions in compounded GLP-1s

The FDA issued a warning letter to Boothwyn Pharmacy, LLC, over its compounded GLP-1 and other products, citing insanitary conditions and products that did not meet their stated strength, quality or purity. The letter was dated January 16, 2026, and published February 10, 2026 ^[1].

Boothwyn is a 503A compounding pharmacy. These pharmacies are state-licensed, and many in the industry have assumed the FDA has no oversight over them. The agency does have jurisdiction over 503A pharmacies for compliance with the Federal Food, Drug, and Cosmetic Act for the compounded products they produce, though these pharmacies are exempt from certain labeling requirements and from the current good manufacturing practices that apply to FDA-approved drugs and to 503B compounded drugs ^[1].

If the violations are not addressed in a satisfactory or timely manner, the FDA can pursue additional advisory action or, without further warning, product recalls, product seizure, injunctions and criminal actions, which could include civil monetary penalties. The agency can also refer the matter to states for action that could affect the licenses of the pharmacy and its pharmacists ^[1].

A wider enforcement push

The Boothwyn letter is one of several recent federal and corporate actions. On September 16, 2025, the FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications, citing misleading direct-to-consumer advertising ^[1]. On February 6, 2026, the FDA said it would take steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products, and warned that entities failing to address violations "may result in legal action without further notice, including, without limitation, seizure and injunction." The announcement named the telehealth company Hims & Hers ^[1].

On February 9, 2026, Novo Nordisk sued Hims & Hers for infringing US Patent No. 8,129,343 with compounded semaglutide products. The company alleged Hims & Hers continued to mass-compound injectable versions of Wegovy made with "inauthentic API," and that its promotions suggested compounded semaglutide products "compare to the safety and efficacy" of Wegovy, "putting patient health and well-being at risk" ^[1].

Timing may matter. Novo Nordisk launched a newly FDA-approved once-daily semaglutide tablet in January 2026. Some compounders had been mass-compounding semaglutide tablets while no approved version existed and were expected to stop once one was available. Instead, Hims & Hers advertised a commercial launch of a compounded semaglutide tablet on February 5, 2026 ^[1]. Also on February 5, TrumpRx launched, listing monthly prices of $149 to $299 for semaglutide tablets, $199 to $349 for semaglutide injections and $299 to $449 for tirzepatide injections, compared with list prices of $1,349, $1,349 and $1,087 ^[1].

Why it matters for patients

The compounded GLP-1 products at issue are not FDA-approved. Under the Federal Food, Drug, and Cosmetic Act, 503A pharmacies are exempt from certain labeling requirements and from the current good manufacturing practices that apply to FDA-approved drugs and 503B compounded drugs ^[1]. The Boothwyn letter found that some compounded products did not match their stated strength, quality or purity ^[1].

Federal rules draw a line between two kinds of compounding. Patient-specific compounding under section 503A, done under a physician's order, is generally allowed; mass compounding by 503B outsourcing facilities was generally permitted only during shortages of the approved GLP-1 products ^[1]. Under 2018 FDA guidance, a compounded product that is "essentially a copy" of an approved drug can be permitted when the prescriber documents on the prescription that the compounded version produces a significant difference for that patient ^[1]. A significant share of customization prescriptions have been written by telehealth prescribers ^[1].

The letter is a cautionary sign to 503A pharmacies operating in this space, and a change in how aggressively those lines are enforced could affect where patients get these medicines and what they pay ^[1].

What happens next

The letter does not set a public deadline for Boothwyn's response, and whether the pharmacy has replied has not been reported ^[1]. The FDA's February 6 statement said it intended to restrict GLP-1 APIs used in compounded products, and Novo Nordisk's lawsuit against Hims & Hers was filed February 9, 2026. Outcomes in both are not yet known ^[1].